canyon landscape

Lundbeck 19386A

Interventional, randomized, double-blind, parallel-group, placebo-controlled delayed-start study to evaluate the efficacy and safety of eptinezumab in patients with episodic cluster headache.

The purpose of this study is to evaluate the efficacy of eptinezumab inpatients with cluster headache.

We anticipate that approximately 304 patients will participate in this study. The study will last for approximately 77 weeks.

Open and enrolling subjects.
Phoenix, Arizona
Total Participants
Primary Sponsor
H. Lundbeck A/S